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Platelet secretion and hemostasis require
syntaxin-binding protein STXBP5
Shaojing Ye,1 Yunjie Huang,1 Smita Joshi,1 Jinchao Zhang,1 Fanmuyi Yang,2 Guoying Zhang,2 Susan S. Smyth,2 Zhenyu Li,2
Yoshimi Takai,3 and Sidney W. Whiteheart1
Department of Molecular and Cellular Biochemistry and 2Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA. 3Department of Biochemistry

1

and Molecular Biology, Kobe University Graduate School of Medicine, Kobe, Japan.

Genome-wide association studies (GWAS) have linked genes encoding several soluble NSF attachment protein receptor
(SNARE) regulators to cardiovascular disease risk factors. Because these regulatory proteins may directly affect platelet
secretion, we used SNARE-containing complexes to affinity purify potential regulators from human platelet extracts.
Syntaxin-binding protein 5 (STXBP5; also known as tomosyn-1) was identified by mass spectrometry, and its expression in
isolated platelets was confirmed by RT-PCR analysis. Coimmunoprecipitation studies showed that STXBP5 interacts with core
secretion machinery complexes, such as syntaxin-11/SNAP23 heterodimers, and fractionation studies suggested that STXBP5
also interacts with the platelet cytoskeleton. Platelets from Stxbp5 KO mice had normal expression of other key secretory
components; however, stimulation-dependent secretion from each of the 3 granule types was markedly defective. Secretion
defects in STXBP5-deficient platelets were confirmed via lumi-aggregometry and FACS analysis for P-selectin and LAMP-1
exposure. Interestingly, STXBP5-deficient platelets had altered granule cargo levels, despite having normal morphology and
granule numbers. Consistent with secretion and cargo deficiencies, Stxbp5 KO mice showed dramatic bleeding in the tail
transection model and defective hemostasis in the FeCl3-induced carotid injury model. Transplantation experiments indicated
that these defects were due to loss of STXBP5 in BM-derived cells. Our data demonstrate that STXBP5 is required for normal
arterial hemostasis, due to its contributions to platelet granule cargo packaging and secretion.

Introduction

Cardiovascular diseases, such as myocardial infarction, stroke,
and deep vein thrombosis, are leading causes of death and disability. These potentially occlusive processes are influenced in part
by platelet secretion (1, 2). As a physiological response to vascular
damage, platelets are activated and secrete components that promote thrombus formation and initiate its sequelae, e.g., wound
healing and angiogenesis (1, 3, 4). Platelet secretion is mediated by
highly conserved soluble N-ethylmaleimide–sensitive factor (NSF)
attachment protein receptor (SNARE) proteins: vesicle/granule
SNAREs (v-SNAREs) consist of the vesicle-associated membrane
proteins (VAMPs), and target membrane SNAREs (t-SNAREs)
consist of 2 classes, syntaxins and members of the synaptosomalassociated protein 23/25 (SNAP23/25) family. A trans-membrane
complex of these 3 proteins mediates bilayer fusion and thus
granule cargo release (5). In human and mouse platelets, this
core fusion complex includes VAMP8, SNAP23, and syntaxin-11
(STX11) (6–9). These core elements are acted on by regulatory
proteins, which affect when and where SNARE interactions occur.
This assures physiologically relevant secretion (10, 11). In platelets,
syntaxin regulators such as Munc18b and tethering proteins such
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as Munc13-4 and Rab27 are required for granule release (1, 12, 13).
Genome-wide association studies (GWAS) have linked other secretory regulators to cardiovascular diseases (14–20); thus, to understand the significance of these associations, it is important to determine which types of SNARE regulators control platelet secretion.
In our continuing effort to identify new secretion regulators, we
used t-SNARE–containing complexes to capture SNARE-binding
proteins from platelet extracts. We identified syntaxin-binding protein 5 (STXBP5; also known as tomosyn-1 [i.e., “friend of syntaxin”]) as a novel candidate for affecting platelet secretion. STXBP5 is
a 130-kDa protein that was originally identified as a STX1-binding
partner in neuronal tissue (21). Subsequent studies have shown
that STXBP5 interacts with other syntaxin isoforms and is widely
expressed (22). STXBP5 belongs to a family of WD40 repeat–containing proteins associated with exocytosis and with the actin cytoskeleton: Sro7/Sro77 in yeast, Tom1 in C. elegans, and STXBP5 in
mammals (23–28). In mammals, 2 genes are present, Stxbp5 and
Stxbp5l (also known as Tomosyn-2), and alternative splicing produces 7 protein isoforms (29, 30). STXBP5 has 3 isoforms, based on
molecular weight: big, middle, and small (b-STXBP5, m-STXBP5,
and s-STXBP5, respectively). Structurally, STXBP5 is composed of
an N-terminal WD40 repeat (~90% of the total protein sequence),
a highly variable linker region, and a C-terminal v-SNARE (or
R-SNARE) motif (30). The v-SNARE motif is proposed to exert a
negative effect on fusogenic SNARE complex assembly by blocking
v-SNARE binding to t-SNAREs (31). Consistently, overexpression
of STXBP5 in neurons and neuroendocrine secretory cells inhibits exocytosis, and gene mutations in C. elegans or genetic deplejci.org   Volume 124   Number 10   October 2014
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Figure 1. STXBP5 is present in human platelets. (A) The indicated complexes were produced in E. coli using the pRSFDuet plasmid with the S-tag
peptide fused to the C terminus of the syntaxin. Complexes were bound
to protein S agarose beads. After washing, the complex-bound beads were
incubated with solubilized human platelet extracts (Plt. ext.). The beads
were washed again, and the proteins were eluted with SDS-PAGE loading
buffer. The eluted proteins were separated by SDS-PAGE and stained with
Sypro Ruby. The specific interacting proteins (T1–T5) were excised, subjected to trypsin digestion, and analyzed by mass spectrometry. The spectra were searched using MASCOT software (see Supplemental Table 1 for
search results). (B) The indicated complexes were produced in E. coli using
the pRSFDuet plasmid with the S-tag peptide fused to the C terminus of
the syntaxin. Solubilized human platelet extracts were incubated with the
different complexes, and the resulting material was recovered on protein
S agarose beads. After washing, the proteins were eluted and probed with
anti-STXBP5 mAb. (C) Analysis of STXBP5 isoforms by RT-PCR. The human
platelet–derived mRNA was converted to cDNA and preamplified by using
either random hexamers or oligo d(T)16 primers, followed by regular PCR
using isoform-specific primers for s-STXBP5, m-STXBP5, and b-STXBP5
(see Methods). The 1-kb DNA ladder standard is at the far left.

tion of Stxbp5 in mice enhances synaptic transmission (24, 32, 33).
However, the N-terminal domain of STXBP5, lacking the syntaxinbinding v-SNARE motif, can also inhibit secretion from PC-12 cells,
which suggests that other interactions with STXBP5 are important
(33). Conversely, knockdown of STXBP5 in superior cervical ganglion neurons (34) and in the rat β cell line INS-1E (35), and genetic
depletion of the homologs Sro7 and Sro77 in yeast (25), negatively
affects exocytosis. Thus, although STXBP5 may be a negative regulator of secretion in some cells, it may play a positive role in others
(24). To date, the role of this potential SNARE regulator in platelets
has not been addressed.
Various studies have linked STXBP5 with neuropsychological
and cardiovascular diseases in humans. Deletions in the Stxbp5
gene are linked to autism (36). GWAS show genetic variations in
Stxbp5 are linked with increased plasma levels of vWF (14–19),
alterations in tissue plasminogen activator (tPA) levels (20),
venous thrombosis (16), and arterial thrombosis (19). Specifically,
1 SNP that produces a nonsynonymous mutation (N436S) was
associated with increased bleeding (18). These associations suggest a role for STXBP5 in both endothelial cell (EC) and platelet
secretion and point to a role for the protein in normal hemostasis.
In the present study, we examined the platelet phenotype of mice
lacking STXBP5 to understand how this t-SNARE regulator affects
platelet exocytosis, granule biogenesis, and hemostasis.

Results

STXBP5 is present in human platelets. The critical SNAREs in platelets have been identified: STX11 and SNAP23 as the t-SNAREs,
and VAMP8 as the primary v-SNARE (6, 8, 9). Of these 3 SNARE
types, syntaxins and their binding proteins have dominated the
ranks of potential secretion regulators, which suggests that syntaxins or syntaxin-containing complexes might serve as useful
“bait” to identify additional secretion regulators. Because of our
problems with the insolubility of STX11 when expressed in bacteria (S. Ye and J. Zhang, unpublished observation), STX2 and
4518
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STX4 were used as surrogates to create syntaxin-SNAP23 and
syntaxin-Munc18 complexes for pulldown assays. Using human
platelet extracts and various syntaxin-containing complexes as
bait, we recovered 5 bands that represented proteins specifically
bound to 1 or more of the syntaxin-containing baits used (Figure
1A). Mass spectrometry analysis showed that bands T1 and T2
were STXBP5, band T3 was phosphofructokinase C, band T4 was
Munc18b, and band T5 was granuphilin (also known as SLP4) (Figure 1 and Supplemental Table 1; supplemental material available
online with this article; doi:10.1172/JCI75572DS1). Munc18b is
known to be required for platelet secretion and to bind to t-SNARE
complexes (13, 37). Granuphilin is a known Rab27 effector and is
important for dense granule secretion (12, 38). The role of phosphofructokinase is unclear at present. STXBP5 has been shown to
be involved in neuronal and neuroendocrine exocytosis (21, 24,
39). Platelet STXBP5 (bands T1 and T2) was specifically associated with t-SNARE heterodimers, consistent with previous reports
showing that STXBP5 forms ternary complexes with STX4/
SNAP23 and STX1/SNAP25 (22, 31). To verify STXBP5 expression
in human platelets and our mass spectrometry results, we probed
platelet extracts and affinity-purified complexes by IB using an
anti-STXBP5 peptide mAb (whose epitope is a region shared by
all 3 isoforms). A specific immunoreactive band was only seen in
samples bound to the t-SNARE heterodimers, not in those bound
to Munc18a- or Munc18c-containing complexes (Figure 1B).
To determine which STXBP5 isoforms were present in human
platelets, RT-PCR analysis was performed using random hexamers and oligo d(T) to prime the reverse transcription step, then
using isoform-specific primers for PCR (29, 40). Only primers for
m-STXBP5 produced a product (Figure 1C), which suggests that
m-STXBP5 is the most abundant isoform in platelets. Expression
of STXBP5 has been consistently reported previously, in the mass
spectrometry analysis of the human platelet proteome by Burkhart
et al. (41) and in a genome-wide RNA sequence analysis of human
and mouse platelets by Rowley et al. (42).
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Figure 2. STXBP5 is associated with platelet SNARE complexes and cytoskeleton. (A–D) Platelet extracts (Input) from resting (R) or thrombin-stimulated
(S) platelets were prepared by solubilization with 1% Triton X-100. After clarification, platelet extracts were incubated with anti-STXBP5 mAb (A) or rabbit
polyclonal Ab (B and D), anti-STX11 rabbit polyclonal Ab (C), anti-Munc18b goat polyclonal Ab (D), or IgG control for 3 hours at 4°C. Immune complexes were
recovered with protein A and G sepharose. The bound proteins were eluted and separated by SDS-PAGE, followed by IB with the indicated antibodies.
(E) Washed platelets (2.5 × 108) were resuspended in HEPES/Tyrode buffer and incubated with (stimulated) or without (resting) 0.1 U/ml thrombin for
5 minutes. After disruption by freeze-thaw, the unbroken cells were removed by centrifugation at 700 g for 5 minutes, and supernatants were subjected to
ultracentrifugation (100,000 g for 1 hour at 4°C). The cytosolic fractions (S1) were collected. The remaining pellets were solubilized sequentially with Triton
X-100 (S2), then n-octyl-β-d-glucopyranoside (S3). The supernatants and insoluble pellet (P) were analyzed by IB with the indicated antibodies. T, total
extract (starting material for the fractionation).

STXBP5 is associated with platelet SNARE machinery. To demonstrate that STXBP5 does interact with the functionally relevant syntaxin isoform in platelets, STX11 (as well as SNAP23
and VAMP8), we immunoprecipitated endogenous STXBP5
from detergent-solubilized extracts and probed the precipitate
with antibodies against known elements of the platelet secretory
machinery. Both resting and thrombin-stimulated human platelets
were lysed with Triton X-100, and immunoprecipitation was performed using nonspecific IgG or an anti-STXBP5 mAb. It should
be noted that much of the platelets STXBP5 was in the pellet fraction under these conditions; however, we chose to focus only on
the soluble pool, so as to lessen the chance of detecting artifactual interactions due to incomplete solubilization. IB showed that
the t-SNAREs STX11 and SNAP23 were recovered in the STXBP5
immunoprecipitates (Figure 2, A and B). Reciprocal immunoprecipitation with anti-STX11 antibodies confirmed this interaction
(Figure 2C). In agreement with the in vitro pulldown results (Figure 1A), endogenous STXBP5 could also bind STX2 and STX4. No
VAMP3 or VAMP8 was detected, consistent with the notion that
STXBP5 competes with v-SNAREs to bind t-SNARE complexes
(31). Another platelet secretory component, Munc18b, was coimmunoprecipitated with STXBP5 (Figure 2B). Reciprocal immunoprecipitation confirmed the STXBP5/Munc18b interaction (Figure
2D). At this stage, it was not mechanistically clear why the complex composition was unaffected by platelet activation. Regard-

less, these data showed that STXBP5 associated with the critical
secretory components SNAP23, STX11, and Munc18b in platelets
and that its association was exclusive of the VAMPs.
STXBP5 localization in platelets. We next sought to determine the distribution of STXBP5 in platelets using biochemical
fractionation and immunofluorescence microscopy. Resting and
thrombin-activated platelets were disrupted by repeated freezethaw and separated into cytosolic and pelleted fractions by centrifugation (Figure 2E). The pelleted fractions were extracted
sequentially with Triton X-100 and n-octyl-β-d-glucopyranoside
to solubilize membrane proteins and lipid raft components,
respectively. The cytosolic marker RabGDI fractionated into the
first supernatant, and the membrane protein marker STX4 was
found in the Triton X-100–solubilized fraction. The raft marker
SNAP23 was present both in the Triton X-100–solubilized fraction and in the n-octyl-β-d-glucopyranoside–solubilized fraction.
STXBP5 was found in the final cytoskeletal pellet, consistent
with actin’s presence (43). The distribution of STXBP5 in platelets (spread on fibrinogen-coated coverslips) was also suggestive of interaction with the cytoskeleton. STXBP5 was concentrated in the central region of the platelets and was surrounded
by phalloidin-stained actin filaments (Figure 3, A–D). Because
these platelets were surface-activated by spreading on coated
glass, few granules remained, but P-selectin staining did appear
in the central area of some platelets (Figure 3, A–D), consistent
jci.org   Volume 124   Number 10   October 2014
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Figure 3. STXBP5 is present in platelets. Washed
human platelets were allowed to bind to fibrinogencoated coverslip for 1 h at 37°C. After washing away
the unbound platelets, the bound platelets were fixed
and immunostained for STXBP5 (A), P-selectin (B) and
F-actin using TRITC-phalloidin (C). Platelets were additionally stained with anti-STXBP5 antibodies (E, I, and
M), anti-tubulin antibodies (G, K, and O) and antibodies against markers for α granules (vWF; F), lysosomes
(LAMP-1; J), and dense granules (CD63; N). Images in
A–D were taken using a Zeiss LSM 780 confocal microscope and processed using ZEN blue software, and
images in E–P were taken using a Nikon A1R confocal
microscope and processed using NIS-Elements AR 3.2
software; D, H, L, and P show 3-color merged views.
Scale bars: 10 μm (A–D); 1 μm (A–D, insets, and E–P).

with this area representing the centralized granulomere of an
activated platelet. Immunofluorescence staining of STXBP5 in
resting platelets, with circumferential tubulin rings, did not show
any obvious colocalization with markers for the 3 specific platelet
granule types (Figure 3, E–P).
STXBP5 is important for platelet secretion. To explore the functional role of STXBP5, we analyzed Stxbp5 KO mice. As might be
predicted from GWAS analysis (14–19), plasma vWF levels were
increased in these mice, although plasma IgG was unaffected, as
indicated by light chain levels (Supplemental Figure 1). Platelet
extracts from Stxbp5 KO and littermate WT mice were prepared
4520
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and subjected to IB analysis. The protein levels of 14 known secretory machinery components were examined; other than STXBP5,
none appeared to be significantly altered (Figure 4A). To understand the role of STXBP5, we examined stimulation-dependent
release of cargo from all 3 platelet granules: dense granules, α
granules, and lysosomes. Secretion of granule cargo from Stxbp5
KO and WT platelets showed the expected thrombin dose dependence (Figure 4B); however, the percentage release from α granules and lysosome was significantly affected by the loss of STXBP5.
The release from dense granules was significantly affected, but to
a lesser extent, in this assay system. The kinetics of secretion from

Downloaded October 17, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI75572.
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Figure 4. STXBP5-deficient mouse platelets
have a secretion defect. (A) Platelet extracts
(5 × 107 platelets/lane) were prepared from
Stxbp5 KO and WT mice, and the indicated
proteins were analyzed by IB. (B and C) [3H]Serotonin–labeled platelets from Stxbp5 KO
and WT mice were prepared as described
in Methods. Release of [3H]-serotonin from
dense granules, PF4 from α granules, and
β-hexosaminidase from lysosomes was measured, and percent secretion was calculated.
(B) Thrombin dose-response experiment;
platelets were stimulated for 1 minute. (C)
Secretion time-course experiment; platelets
were stimulated with 0.1 U/ml thrombin.
Data are mean ± SEM of triplicate measurements. Significant P values (2-way ANOVA)
are indicated.

Stxbp5 KO platelets was also significantly defective upon activation with 0.1 U/ml thrombin (Figure 4C).
Because dense granule release is such a rapid process, measuring [3H]-serotonin release in our assay configuration at room temperature (Figure 4, B and C) may not be sufficient to fully appreciate a subtle, albeit significant, kinetic defect. To rectify this, we
applied more sensitive lumi-aggregometry to analyze ATP/ADP
release from dense granules. ATP/ADP release in response to
100 μM PAR-4, 10 nM A23187, 0.1 μg/ml convulxin, and 0.025,
0.05, and 0.1 U/ml thrombin was substantially inhibited, whereas
aggregation was not (Figure 5). Quantification of ATP/ADP release
from 3 independent experiments showed significant reductions in
Stxbp5 KO platelets (Figure 5, D and K). To further confirm that
STXBP5 is required for α granule and lysosome release, exposure
of the respective markers P-selectin and LAMP-1 was analyzed
by flow cytometry. Consistently, activation-dependent exposure
of both granule membrane markers was reduced approximately
2-fold in Stxbp5 KO versus WT platelets (Figure 6, A and B).
In agreement with the aggregation data, there was no significant difference in PE-conjugated JonA staining (Figure 6C),
which suggests that depletion of STXBP5 did not affect integrin
αIIbβ3 activation (15, 44, 45). Electron microscopy (EM) analysis
detected no overt morphology differences in Stxbp5 KO platelets
(Supplemental Figure 2). Upon thrombin stimulation, there was
similar filopodia formation in both WT and Stxbp5 KO platelets,
which suggests that deficiency of STXBP5 did not affect platelet
cytoskeletal rearrangements or platelet activation, but did affect
secretion. Additionally, adhesion to fibrinogen was not affected in
Stxbp5 KO platelets, although there was a clear defect in spreading
on fibrinogen (Supplemental Figure 3). This is consistent with the
role of granule secretion in platelet spreading (46).
STXBP5 is important for platelet granule cargo packaging. As we
measured cargo release as a percentage of total, we also detected a

decrease in platelet factor 4 (PF4) in Stxbp5 KO versus WT platelets
(Table 1). Serotonin and β-hexosaminidase levels were not significantly reduced; in fact, total serotonin levels and uptake of [3H]serotonin were increased by approximately 60% (Table 1). These
data suggest that STXBP5 contributes to granule biogenesis as well
as to secretion. To characterize the effect of STXBP5 loss on platelet cargo, we probed extracts with granule-specific antibodies (Figure 7, A and B). IB data confirmed the reduction of PF4 and showed
reduced levels of factor V. Platelet fibrinogen and vWF levels were
modestly affected. The total levels of granule membrane proteins
(e.g., LAMP-1 and P-selectin) were only slightly affected, while the
surface expression of several platelet markers (e.g., GP1bβ, GPVI,
and PECAM-1) was largely unaffected (Figure 7, B and C). Consistent with the levels of LAMP-1 and P-selectin, EM analysis showed
no significant difference in the number of granules present per
platelet section when dense and α granules were counted (Table 1).
These data argue that granules are made, but may not be normally
loaded with cargo. Further analysis of soluble cargo levels yielded
a complex phenotype. Antibody array analysis showed that several
cargo proteins were reduced in Stxbp5 KO platelets. Others were
unchanged, and a few, including MMP-9, showed robust increases
(Figure 7D). All cargo proteins tested were detectable at some level
(Supplemental Figure 4). These data indicate that STXBP5 contributes to the efficacy — and perhaps the selectivity — of granule cargo
packaging, but is not essential for the process.
STXBP5 is important for hemostasis. The primary function of
platelet secretion is in hemostasis. To assess whether STXBP5
contributes to hemostasis, we used 2 in vivo assays. First, a tail
bleeding time assay was performed on 5- to 6-week-old mice.
Whereas the 19 WT littermates showed an average bleeding time
of 226.4 ± 37.3 s, of the 24 Stxbp5 KO mice, only 3 had normal
bleeding times; the remainder bled excessively until the study
was ended at 10 minutes (Figure 8A). The prolonged tail bleedjci.org   Volume 124   Number 10   October 2014
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Figure 5. Depletion of STXBP5 in platelets
affects ATP/ADP release, but not aggregation. Aggregation (A–C and H–J) and ATP/
ADP release (D–G and K–N) were monitored simultaneously in a lumi-aggregometer. Washed platelets (2.0 × 105/μl) from
Stxbp5 KO and WT mice were stimulated
with 100 μM PAR-4 peptide (A and E), 10
nM A23187 (B and F), 0.1 μg/ml convulxin
(C and G), or thrombin (Thr) at 0.025 U/ml
(H and M), 0.05 U/ml (I and N), or 0.1 U/ml
(J and O) for 3 minutes. (A–C, E–J, and L–N)
Representative traces from 1 experiment.
(D and K) Mean ± SEM ATP/ADP release
from 3 independent experiments.
*P < 0.01, 2-way ANOVA.

ing of the Stxbp5 KO mice indicates that STXBP5 is required for
hemostasis in this transection injury model.
In agreement with the tail bleeding, there was a robust thrombus formation defect observed in Stxbp5 KO mice in response
to FeCl3 injury of the carotid artery. The average time required
to form a stable thrombus in WT littermates was 2.7 ± 0.2
minutes, in contrast to 27.7 ± 2.3 minutes for Stxbp5 KO mice
(Figure 8B), which indicates that STXBP5 is critical for hemostasis in this arterial injury model.
Platelet counts were not significantly different in Stxbp5
KO and WT littermate mice, although the former exhibited an
increase in mean platelet volume (Table 1); therefore, thrombocytopenia is unlikely to be the cause of the bleeding diathesis. The combination of cargo and secretion deficiencies in the
Stxbp5 KO platelets could account for the robust bleeding, but
since the mouse strain is a global deletion, other processes could
precipitate the hemostatic defects. To address whether the loss
of STXBP5 in BM-derived platelets accounted for the hemostatic defect, BM chimeras were constructed via transplantation:
Stxbp5 KO BM was grafted into WT recipients, and vice versa.
When Stxbp5 KO BM was grafted into WT recipients, there was
a significant increase in bleeding times in the resulting chimeras
compared with WT BM grafted into Stxbp5 KO recipients (Figure
8C). Similarly, occlusion times in the carotid injury model were
significantly prolonged in Stxbp5 KO BM–grafted WT chimeric
mice (Figure 8D). These results suggest that loss of STXBP5 in
4522
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BM-derived hematopoietic cells (e.g., platelets) contributes to
the robust bleeding defect observed (Figure 8, A and B). Since the
Stxbp5 KO animals grafted with WT BM had a normal bleeding
profile, it seems unlikely that loss of STXBP5 affects coagulation
factors, although this was not directly measured. In summary,
these results indicate a role for STXBP5 in platelet granule packaging and secretion and in arterial hemostasis.

Discussion

The novel findings herein were that STXBP5 was required for normal platelet secretion, granule cargo packaging, and hemostasis.
This requirement of STXBP5 for platelet exocytosis diverges from
the protein’s proposed role as a negative regulator in neuronal cell,
neuroendocrine cell, and EC secretion (21, 24, 39, 47). Our present data indicate that STXBP5 may be important for cardiovascular health, as echoed in recent GWAS in which STXBP5 has been
linked to thrombosis (14–20).
Platelet granule release requires the secretory machinery
components that are universally used for regulated secretion:
SNAREs, Munc18, Rabs, and Munc13 (48). Much of the published data suggest that STXBP5 is a negative regulator of secretion, competing with v-SNAREs for t-SNARE binding. As in
those prior studies, we showed here that STXBP5 interacted with
t-SNARE–containing complexes and that its presence was exclusive of at least 2 platelet v-SNAREs (Figure 2). However, deletion
of STXBP5, as well as inclusion of an anti-STXBP5 antibody into
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Figure 6. Deletion of STXBP5 inhibits P-selectin
and LAMP-1 exposure, but not integrin activation. Washed platelets (2 × 106) from Stxbp5 KO
and WT mice were stimulated with or without
0.1 U/ml thrombin for 1 minute and then incubated with FITC-conjugated anti–P-selectin (A),
FITC-conjugated LAMP-1 (B), or PE-conjugated
JonA (C) Abs for 15 minutes at room temperature. Fluorescence intensities were measured
by flow cytometry. Shown are representative
data (black lines, resting; gray lines, stimulated)
and geometric MFI (mean ± SEM) of 3 independent experiments. Significant P values (2-way
ANOVA) are indicated.

a permeabilized platelet secretion assay, inhibited rather than
enhanced platelet secretion (Figures 4–6 and Supplemental Figure 5). This result raises the question of how STXBP5 could have a
positive effect on exocytosis. Studies in Drosophila show that loss
of STXBP5 prolongs the excitatory junctional currents (EJCs) at
neuromuscular junctions (NMJs) (49). This could be due to ectopic vesicle priming (adjacent to active zones) or prolonged fusion
pore opening, which suggests that the role of STXBP5 is to spatially restrict vesicle priming and/or fusion. In platelets, spatial granule priming for exocytosis may be critical for efficacious secretion. While our in-suspension secretion assays (Figures 4–6) may
be less influenced by a loss of polarization, secretion in a forming thrombus almost assuredly needs to be polarized (50). Thus,
STXBP5 may be important for normal thrombosis, and its deletion would cause the hemostasis defects we observed (Figure 8).
At this stage, it is unclear why STXBP5 is important for secretion
from yeast (25), INS-1E cells (35), or platelets (Figures 4–6); however, its interactions with cytoskeleton (Figure 2E and Figure 3),
especially myosin Va (28, 42, 51), may hint at a role in spatially
coordinating SNARE complexes for membrane fusion and subsequent secretion. STXBP5 interactions with cytoskeleton could
contribute to granule biogenesis by directing the trafficking of
cargo proteins to α granules forming in megakaryocytes. The
heterogeneity in cargo levels we observed herein (Figure 7 and
Supplemental Figure 4) may be indicative of multiple pathways
for granule cargo sorting and packaging. Further work will be
required to address these potential functions of STXBP5.
GWAS have linked SNPs in STXBP5 to alterations in vWF
levels (14–19) and tPA levels (18). Loss of STXBP5 increases vWF
release from ECs (47), but decreases tPA release (20). These

results highlight potentially conflicting roles for STXBP5 in ECs,
which may relate to which granules are being released. vWF and
tPA are enriched in different granules in ECs (52). Combining
these 2 effects, heightened vWF and decreased tPA, might be
expected to increase thrombotic risk, consistent with the premise
of the GWAS. Conversely, an SNP encoding a nonsynonymous
substitution in STXBP5 (N436S) has been linked to increased
bleeding in a female population homozygous for the allele (18).
The dramatically prolonged bleeding times in the tail transection
model and the hemostasis defects in the FeCl3-induced carotid
artery injury model we observed in Stxbp5 KO mice and in Stxbp5
KO BM–grafted WT mice are consistent with this prior report and
support a connection between STXBP5 and bleeding risk. At this

Table 1. Properties of WT and Stxbp5 KO mouse platelets
Platelet count (×1,000/μl)
Mean platelet volume (fl)
Serotonin (μM/108 platelets)A
3
[H]-Serotonin uptake (cpm/108 platelets)
PF4 (pg/106 platelets)
β-Hexosaminidase (nMh–1/106 platelets)
Dense granules/plateletB
α Granules/plateletB

WT

Stxbp5 KO

P

824 ± 123
4.20 ± 0.23
6.31 ± 0.5
2,515 ± 224
1,690 ± 120
54 ± 10
0.46 ± 0.57
7.97 ± 1.80

881 ± 101
6.28 ± 0.10
10.64 ± 1.4
4,101 ± 545
545.5 ± 15
57 ± 11
0.52 ± 0.57
7.84 ±1.22

0.561
0.001
0.006
0.036
<0.0001
0.878
0.320
0.453

P values were calculated using Student’s t test. ADetermined using the
fluorescence o-phthalaldehyde assay (see Supplemental Methods).
B
Granules in each platelet in an EM section were counted (n = 200 platelets
counted).
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Figure 7. STXBP5-deficient mouse platelets have a complex granule cargo defect. (A and B) Platelet extracts (5 × 107 platelets/lane) were prepared
from 3 individual Stxbp5 KO or WT mice. The indicated proteins were analyzed by IB (A) and quantified with Image Lab 4.0.1 or ImageQuant TL. After
normalization using RabGDI as loading control, the Stxbp5 KO/WT ratio was calculated (B). (C) Washed platelets (2 × 106) from 3 individual Stxbp5 KO or
WT mice were incubated with FITC-conjugated anti-GP1bβ, anti-αIIbβ3, anti-GPVI, or anti–PECAM-1 for 15 minutes at room temperature. Geometric MFI
(mean ± SEM) was determined using flow cytometry. (D) Antibody array analysis of platelet extracts. Extracts were prepared from WT or Stxbp5 KO mice
and probed using duplicate Proteome Profiler Mouse Angiogenesis Antibody Arrays (see Methods). The fluorescence intensity from 2 experiments was
used to calculate a Stxbp5 KO/WT ratio for each protein detected on the array. The average of the 2 calculated ratios is plotted. Note that the y axis is a
log scale. SDF-1, PF4, and angiopoietin 1 were excluded from analysis due to saturation of their respective spots on the array membranes.

stage, it is unclear whether the N436S substitution has any effect
on STXBP5 stability or function.
Zhu et al. have shown that loss of STXBP5 enhances EC secretion of vWF and increases platelet binding to activated ECs (47).
Consistent with our results (Supplemental Figure 1), Zhu et al.
showed significantly increased plasma vWF levels in Stxbp5 KO
mice (47). Clearly, the increased vWF is not sufficient to offset the
platelet secretion defect described herein, since we observed bleeding tendencies in the 2 arterial hemostasis models tested (Figure 8).
However, venous thrombi are mainly composed of fibrin and red
blood cells, whereas arterial thrombi are dominated by platelets
and fibrin; therefore, it is possible that STXBP5-mediated platelet
secretion is more important for arterial hemostasis. It remains to be
determined how the loss of STXBP5 affects venous thrombosis.
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In summary, our data provide a potential explanation for the
GWAS (14–19) linking STXBP5 with cardiovascular disease risk.
Our findings showed that STXBP5 was present in platelets and was
important for cargo release from dense granules, α granules, and
lysosomes as well as for packaging of some cargo into granules.
Mice with platelets deficient in STXBP5 displayed robust defects
in thrombus formation in 2 arterial hemostasis models, consistent with the granule biogenesis and release defects. Our data
add another component to the pathway of protein-protein interactions that culminates in platelet secretion. They also suggest that
platelets may be a useful system for understanding how STXBP5
positively affects exocytosis in other systems, perhaps through its
associations with cytoskeleton. Moreover, platelet STXBP5 may
be a useful diagnostic marker for cardiovascular diseases.
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Figure 8. Hemostasis and thrombus formation are impaired in
STXBP5-deficient mice. (A) Tail bleeding times were measured
after tail transection from Stxbp5 KO (n = 24) and WT (n = 19) littermates. (B) Thrombus formation in the carotid artery was induced
by topical application of 5% FeCl3, and blood flow was monitored
from Stxbp5 KO (n = 10) and WT (n = 9) littermates. (C and D)
Chimeric mice (WT BM transplanted into Stxbp5 KO littermates
[WT→KO], n = 7; Stxbp5 KO BM transplanted into WT littermates
[KO→WT], n = 5) were analyzed using the same assays. Tail
bleeding times (C) and the time to blood flow cessation from 5%
FeCl3-induced carotid thrombosis (D) were measured. Each symbol
represents an individual mouse; mean ± SEM are noted. P values
(log-rank test) are indicated.

Methods

Antibodies and reagents. Anti-STXBP5 mAb (611296), anti-Rab27a mAb
(clone 20.1), anti-PECAM, FITC-conjugated anti-mouse P-selectin,
and unconjugated anti-mouse P-selectin were from BD Biosciences. A
rabbit anti-STXBP5 polyclonal Ab (HPA039991) was from Atlas Antibodies. The anti–hLAMP-1 (H4A3) and anti-hCD63 (H5C6) mAbs were
from the University of Iowa Developmental Studies Hybridoma Bank.
Anti-Munc18b (sc-14563) polyclonal Ab was from Santa Cruz. Antibodies against STX2, STX4, STX7, SNAP23, VAMP8, Munc18c, RabGDI, VAMP2 (synaptobrevin), VAMP3 (cellubrevin), VAMP7, VAMP8
(endobrevin), and Munc13-4 were as described previously (6, 8, 53).
Anti-STX11 polyclonal Ab and anti-Munc18a mAb (clone 131.1) were
purchased from Synaptic System GmbH. PE-conjugated JonA mAb,
anti-GP1bβ, and anti GPVI Abs were purchased from Emfret Analytics.
Anti-human fibrinogen and anti-vWF polyclonal Abs were from Dako.
The anti–integrin β3 antibody and the Alexa Fluor 647–labeled rabbit
anti–α-tubulin antibody (11H10) were from Cell Signaling. The anti–
factor V antibody was provided by B. Bouchard (University of Vermont,
Burlington, Vermont, USA). A STXBP5 expression vector (provided by
U. Ashery, Tel Aviv University, Tel Aviv, Israel) was used to make antigens for the production and purification of a polyclonal anti-STXBP5
antibody (see Supplemental Methods). Anti–β-actin antibody and
alkaline phosphatase–conjugated anti-IgGs were from Sigma-Aldrich.
Protein A–conjugated sepharose, 2-methyl-2-butanol, 2,2,2 tribromoethanol (Avertin), and FeCl3 were from Sigma-Aldrich. The rest of the
materials used in this study were of reagent grade.
Protein production. Expression plasmids to create complexes of
full-length human SNAP23, Munc18a, and Munc18c and the cytoplasmic domains of human STX2 (aa 1–251) and STX4 (aa 1–265)
were constructed using pRSFDuet-1 (Novagen) and confirmed by
DNA sequencing. All syntaxin-containing complexes were expressed
in E. coli and purified using Ni2+-NTA (6) and S-protein (Novagen)
affinity chromatography.
RT-PCR. Identification of STXBP5 isoforms was performed as
described previously (29, 40), with slight modification. Human platelets were isolated from banked, platelet-rich plasma (13), total RNA
was isolated using QIAamp RNA Blood Mini Kit (QIAGEN), and cDNA
was synthesized using TaqMan Reverse Transcription Reagents Kit
(Applied Biosystems). PCR amplification was performed using primers

specific for the b-STXBP5 (5′-CTCCGACTTCCGGTTCTTCCTC-3′
and 5′-TTCAGCGTGATGACAAAGGC-3′), m-STXBP5 (5′-CTCCG
ACTTCCGCAAAGATGTC-3′ and 5′-TTCAGCGTGATGACAAAG
GC-3′), and s-STXBP5 (5′-CTCCGACTTCCGATGTGAAAG-3′ and
5′-TTCAGCGTGATGACAAAGGC-3′) isoforms (29, 40).
Immunoprecipitation of STXBP5-interacting proteins. Washed
platelet suspensions (109 platelets) were lysed with equal volumes
of 2× lysis buffer (100 mM HEPES/KOH, pH 7.4; 2% Triton X-100;
2 mM EGTA; 2 mM EDTA; 150 mM NaCl; and 2× protease inhibitor
cocktail) on ice for 30 minutes. The lysates were clarified by centrifugation, and the supernatants were precleared with protein G/A
sepharose (GE Healthcare). The interacting proteins were immunoprecipitated with anti-STXBP5, anti-Munc18b, or anti–Munc13-4 Abs,
followed by incubation with protein G sepharose. The immunoprecipitates were recovered by centrifugation, washed with lysis buffer, and
analyzed by SDS-PAGE and IB.
Genotyping of Stxbp5 KO mice. Stxbp5 KO mice on a 50% 129Sv, 25%
C57BL/6, and 25% DBA/2 background were generated as previously
described (32). Heterozygous embryos of Stxbp5 KO mice were recovered into live mice by the Jackson Laboratory. Genotype was determined
by PCR using DNA isolated from tail tip biopsies. The primers used were
as follows: Stxbp5 KO forward, 5′-GGGCGCCCGGTTCTTTTTGTC-3′;
Stxbp5 KO reverse, 5′-GCCATGATGGATACTTTCTCG-3′; WT forward, 5′-TTCTGCTCCCCGCTGCTCCTT-3′; WT reverse, 5′-TCCCCGCTCCCTTCACCTTGC-3′. PCR products were 224 bp for the Stxbp5
KO allele and 300 bp for the WT allele.
Measurement of secretion from intact platelets. The secretion assay
was carried out as described previously (13); see Supplemental Methods for details. Briefly, washed platelets were labeled with [3H]-serotonin (0.4 μCi/ml) for 1 hour at 37°C. After washing with HEPES/
Tyrode buffer (10 mM HEPES/NaOH, pH 7.4; 5.56 mM glucose;
137 mM NaCl; 12 mM NaHCO3; 2.7 mM KCl; 0.36 mM KH2PO4; and
1 mM MgCl2) in the presence of 0.2 U/ml apyrase, the platelets were
resuspended and adjusted to 2.5 × 105/μl. For titration experiments,
the indicated concentrations of thrombin were added, and the reactions were stopped at 1 minute with a 2-fold excess of hirudin. For
time course experiments, 0.1 U/ml thrombin was added for the
indicated times, and reactions were stopped with hirudin. Supernatants and pellets were recovered after centrifugation at 13,000 g for
jci.org   Volume 124   Number 10   October 2014
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1 minute, and the pellets were lysed with an equal volume of lysis
buffer (PBS, pH 7.4, and 1% Triton X-100) for 1 hour on ice. Both
supernatants and pellets were assayed for 3 granule cargo markers:
[3H]-serotonin for dense granules by scintillation counting, platelet
factor 4 (PF4) for α granules by ELISA, and β-hexosaminidase for
lysosomes by colorimetric assay using p-nitrophenyl-N-acetyl-βd-glucosaminide, as previously described (54). Secretion was then
calculated as (supernatant/[supernatant + pellet]) and expressed as
a percentage; the analysis yields a measurement of total cargo content (supernatant plus pellet) and allows for assessment of secretion
efficacy independent of cargo content.
Immunofluorescence microscopy. Platelet preparation and immuno
staining were performed as previously described (55), with slight
modification. Briefly, sterile glass coverslips were coated with 50
μg/ml human fibrinogen for 24 hours at 4°C. Washed platelets were
placed onto fibrinogen-coated coverslips for 1 hour at 37°C. Platelets
were fixed with 4% paraformaldehyde for 15 minutes and quenched
with 50 mM NH4Cl. Cells were rinsed with 10% FBS/PBS and incubated with the indicated primary antibodies in 10% FBS/PBS containing 0.2% saponin O/N at 4°C. After washing with 10% FBS/PBS, cells
were incubated with the appropriate fluorophore-conjugated anti-IgG
secondary antibody for 2 hours. After washing, some samples were
incubated with TRITC-conjugated phalloidin in 10% FBS/PBS with
0.2% saponin. Coverslips were mounted and examined with a LSM
780 confocal microscope (Carl Zeiss), and images were processed
using ZEN blue software (Carl Zeiss). Additional imaging was done
using a Nikon A1R confocal microscope, and images were processed
using NIS-Elements AR 3.2 software (Nikon).
Platelet aggregation and ATP/ADP release. Murine platelets (2.5 × 105/
μl) were prepared (13), recalcified with 0.7 mM CaCl2, placed into siliconized cuvettes, and stirred for 3 minutes at 37°C at 1,200 rpm. Luciferinluciferase substrate was added, followed by the indicated agonists, and
the percent change in light transmission was measured. Aggregation and
ATP/ADP secretion were monitored using a Model 460VS Lumi-Dualaggregometer, and traces were acquired using a Model 810 Aggro/Link
interface with Aggro/Link software (all from Chrono-Log).
Flow cytometry analysis. Washed murine platelets (2 × 106) were
kept as resting or were stimulated with thrombin (0.1 U/ml) for 1 minute, after which the reaction was stopped with hirudin. After incubation with antibodies (5 μl) for 15 minutes at room temperature, the
reactions were diluted 10-fold with HEPES/Tyrode buffer (pH 6.5).
The samples were transferred to tubes, and fluorescence intensities
were measured using a FACScan flow cytometer and analyzed using
CellQuest (BD Biosciences).
Tail bleeding assay. Tail vein bleeding times were determined as
previously described (56). Briefly, 5- to 6-week-old mice were anesthetized with ketamine (75 mg/kg i.p.). Tails were transected 3 mm
from the tip and immersed in saline at 37°C. The time from incision to
bleeding cessation was recorded. Animals were observed for an additional minute to assess rebleeding. Prolonged bleeding was stopped
manually after 10 minutes. Statistical analysis was performed using
the log-rank test (GraphPad Prism 5).
FeCl3-induced arterial hemostasis model. The FeCl3-induced arterial thromobosis model was as previously described (57). Briefly,
mice 8–12 weeks of age were anesthetized with Avertin (0.2 g/kg
i.p.) and placed on a 37°C heating pad. The left carotid artery was
exposed, and a Doppler TS420 flowmeter (0.5VB; Transonic System
4526
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Inc.) was placed on the artery to monitor blood flow. Thrombus formation was induced by placing a small piece of filter paper, saturated
with 5% FeCl3 solution, on the vessel for 3 minutes. Time from application to cessation of flow was measured. Experiments were terminated at 30 minutes. Statistical analysis was performed using the
log-rank test (GraphPad Prism 5).
BM transplantation mouse model. BM transplantation was performed as previously described (58), with some modification. Briefly,
BM harvested from femurs and tibias of 6-week-old WT or Stxbp5 KO
mice was resuspended with 10 mM HEPES, pH 7.4 buffer containing
25 U/ml heparin and 5% FBS and adjusted to 5 × 107 cells/ml. The cell
suspension (0.1 ml) was injected into the retroorbital sinus of lethally
irradiated mice. After 6 weeks of recovery, tail bleeding and FeCl3induced hemostasis assays were performed. Statistical analysis was
performed using the log-rank test (GraphPad Prism 5).
Subcellular fractionation of platelets. Human platelets were resuspended in HEPES/Tyrode buffer (pH 7.4) and treated with or without
0.1 U/ml thrombin for 5 minutes. The resting and activated platelets
were disrupted by 5 freeze-thaw cycles. After disruption, the unbroken
cells were removed by centrifugation at 700 g for 5 minutes, and the
supernatants were fractionated by ultracentrifugation at 100,000 g
for 1 hour. The supernatant (cytosol) was collected, and the resulting pellets were solublized with 1% Triton X-100, incubated on ice
for 15 minutes, and then subjected to centrifugation at 100,000 g
for 1 hour. The supernatant (Triton X-100–soluble fraction) was collected, and the resulting pellets were solublized with 1% n-octyl-β-dglucopyranoside, incubated on ice for 15 minutes, and then subjected
to centrifugation at 100,000 g for 1 hour. The supernatant (n-octylβ-d-glucopyranoside–soluble fraction) was collected. The detergentinsoluble pellets were solublized in SDS-PAGE loading buffer. The
supernatants (soluble fractions) and pellets (detergent-insoluble fractions) were probed by IB using anti-STXBP5, anti-RabGDI, anti-STX4,
anti-SNAP23, and anti–β-actin antibodies.
Angiogenesis antibody array analysis of platelet granule cargo. Proteome Profiler Mouse Angiogenesis Antibody Array (ARY 015; R&D
Systems) was used according to the manufacturer’s instructions.
Briefly, the nitrocellulose membranes were first incubated in blocking
buffer for 1 hour. Platelet extracts (from 108 platelets) were prepared in
1 ml lysis buffer (1% NP-40; 20 mM Tris-HCl, pH 8.0; 137 mM NaCl;
10% glycerol; 2 mM EDTA; and 10× protease inhibitor cocktail) and
mixed with a cocktail of biotin-labeled detection antibodies against
different individual angiogenesis-related proteins. After incubation
for 1 hour, the mixture of the platelet sample and detection antibodies was then incubated with the nitrocellulose membranes O/N at 4°C.
The membranes were washed 3 times and incubated with HRP-conjugated streptavidin for 30 minutes. After washing the membranes 3
times, the signals for each array spot were detected with Supersignal
ELISA Femto Maximum Sensitivity Substrate (Thermo-Scientific)
using a ChemiDoc MP System (BioRad). The array experiments were
run in duplicate. Fluorescence intensities for each spot were measured, background was subtracted, and the Stxbp5 KO/WT ratio was
calculated and plotted using SigmaPlot (version 12.0; Systat Software
Inc.). Under these conditions, spots for 3 proteins — SDF-1, PF4, and
angiopoietin 1 — were saturated, and thus failed to yield quantitative
data (Supplemental Figure 4). These were excluded from analysis.
Statistics. Data from bleeding time and occlusion assays were analyzed by log-rank test. Data from secretion assays and FACS-based
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experiments were analyzed by 2-way ANOVA. A 1-tailed Student’s t
test was used to analyze the properties of platelets from Stxbp5 KO and
WT mice. A P value less than 0.05 was considered significant.
Study approval. Animal procedures were approved by the IACUC
of University of Kentucky. Human samples were from anonymized
units; thus, no IRB approval or informed consent was required.
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